Patent ID: 8759005

Claim:
A method of evaluating the status of a human tissue material preparation comprising the step of detecting the presence of a glycan structure in said preparation, wherein the detection is performed by mass spectrometry or by an antibody, lectin, or enzyme specifically binding to said glycan structure, wherein the amount of the glycan structure is determined in comparison to the same glycan structure from control tissue, which is healthy tissue or tissue altered by disease or another cell line or cell sample derived from the same tissue and wherein said glycan structure consists of a terminal non-reducing end structure according to [Mα2] n1 [Mα3] n2 {[Mα2] n3 [Mα6)] n4 }[Mα6] n5 {[Mα2] n6 [Mα2] n7 [Mα3] n8 }Mβ4GNβ4([{Fucα6}] m GNyR 2 ) z Formula Mn: wherein n1, n2, n3, n4, n5, n6, n7, n8, and m, and z are either independently 0 or 1; with the proviso that when n2 is 0, also n1 is 0; when n4 is 0, also n3 is 0; when n5 is 0, also n1, n2, n3, and n4 are 0; when n7 is 0, also n6 is 0; when n8 is 0, also n6 and n7 are 0; y is anomeric linkage structure α and/or β or linkage from derivatized anomeric carbon, and R 2 is reducing end hydroxyl, chemical reducing end derivative or natural asparagine N-glycoside derivative and/or peptides derived from protein; [ ] and ( ) indicates determinant either being present or absent depending on the value of n1, n2, n3, n4, n5, n6, n7, n8, and m; and { } indicates a branch in the structure, M is mannose residue (Man) and GN is N-acetylglucosaminyl residue (GlcNAc) with the provisions that i) z is 0 indicating soluble mannose-GlcNAc1-glycome, or ii) the structure comprises 5 or less mannose residues or iii) m is 1 and there are 6 or less mannose units.